{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:44:15Z","timestamp":1790837055116,"version":"4.1.0"},"reference-count":93,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T00:00:00Z","timestamp":1658534400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Some non\u2010factor products that work by facilitating the coagulation pathway (emicizumab) and blocking the anticoagulant pathway (fitusiran, concizumab and marstacimab) for patients with haemophilia (H) have been developed, and clinical trials using these products are currently ongoing. Prophylaxis using non\u2010factor products by subcutaneous administration provides marked reductions of bleeding episodes in patients with HA or HB, regardless of the presence of inhibitor. Emicizumab has already been approved globally. Emicizumab alters the phenotype of patients with HA from severe to mild by maintaining trough levels of equivalent factor VIII activity (15\u201320\u00a0iu\/dl). Phase 3 clinical trials and long\u2010term observations assessing emicizumab revealed tolerable safety and efficacy. However, thrombotic events have occurred in patients receiving these non\u2010factor products. Furthermore, monitoring of the haemostatic function of these products with concomitant therapy is also required in clinical practice. These products have promising haemostatic efficiency, but wider clinical experience is needed to provide optimal therapeutic strategies in the future.<\/jats:p>","DOI":"10.1111\/bjh.18379","type":"journal-article","created":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T07:09:36Z","timestamp":1658560176000},"page":"23-34","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Current and future therapies for haemophilia\u2014Beyond factor replacement therapies"],"prefix":"10.1111","volume":"200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2415-2194","authenticated-orcid":false,"given":"Keiji","family":"Nogami","sequence":"first","affiliation":[{"name":"Department of Pediatrics Nara Medical University  Kashihara Nara Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Midori","family":"Shima","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Nara Medical University  Kashihara Nara Japan"},{"name":"Thrombosis and Hemostasis Research Centre Nara Medical University  Kashihara Nara Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,7,23]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615621"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.5435\/00124635-200407000-00004"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067659"},{"issue":"1","key":"e_1_2_8_5_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169880","article-title":"Adherence to prophylaxis in adolescents and Young adults with severe haemophilia: a quantitative study with patients","volume":"12","author":"Os SB","year":"2017","journal-title":"PLoS One"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199302183280701"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2942"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3847"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-401620"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-650226"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1511769"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017006684"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703068"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001869"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803550"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30054-7"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13848"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14205"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14046"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH09-10-0732"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13820"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-801662"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH17-01-0030"},{"issue":"2","key":"e_1_2_8_24_1","first-page":"193","article-title":"Regulation of factor VIIIa in the intrinsic factor Xase","volume":"82","author":"Fay PJ","year":"1999","journal-title":"Thromb Haemost"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2018.04.016"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14334"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13961"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1636538"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15525"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1710032"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M708985200"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14556"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-118379"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12670"},{"issue":"2","key":"e_1_2_8_35_1","article-title":"Final analysis of the STASEY trial: a single\u2010arm, multicenter, open\u2010label, phase III clinical trial evaluating the safety and tolerability of emicizumab prophylaxis in persons with hemophilia A (PwHA) with factor (F)VIII inhibitors","volume":"5","author":"Jim\u00e9nez\u2010Yuste V","journal-title":"Res Pract Thromb Haemost"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146009"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009217"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15187"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14022"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14887"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14491"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13871"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13817"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16574"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14353"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13819"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13762"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13166"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-483263"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.12427"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1721385"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1710315"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12474"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-021-03276-7"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13990"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-019-02698-8"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-021-03095-w"},{"key":"e_1_2_8_58_1","first-page":"203","article-title":"Evaluation of emicizumab calibrator and controls with a modified one\u2010stage FVIII assay on an automated coagulation analyser","volume":"3","author":"Shinohara S","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13903"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14135"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057479"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15506"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14957"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-585737"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006315"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.1177\/20406207211038193"},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14450"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14746"},{"key":"e_1_2_8_69_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0041-1725009"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14209"},{"key":"e_1_2_8_71_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000656"},{"key":"e_1_2_8_72_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14491"},{"key":"e_1_2_8_73_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14272"},{"key":"e_1_2_8_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2020.11.026"},{"key":"e_1_2_8_75_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14581"},{"key":"e_1_2_8_76_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0038104"},{"key":"e_1_2_8_77_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-11-465674"},{"key":"e_1_2_8_78_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcibr1505657"},{"key":"e_1_2_8_79_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1604053"},{"key":"e_1_2_8_80_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.115.305996"},{"key":"e_1_2_8_81_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12897"},{"key":"e_1_2_8_82_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14207"},{"key":"e_1_2_8_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2012.02.030"},{"key":"e_1_2_8_84_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1616569"},{"key":"e_1_2_8_85_1","article-title":"Fitusiran, an investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia: interim results from a phase 2 extension study in patients with hemophilia A or B with and without inhibitors","volume":"1","author":"Pasi KJ","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"key":"e_1_2_8_86_1","first-page":"2366","article-title":"Perioperative management on patients with hemophilia receiving fitusiran, an inventing RNAi therapeutic targeting antithrombin for the treatment of hemophilia","volume":"130","author":"Negrier C","year":"2017","journal-title":"Blood"},{"key":"e_1_2_8_87_1","unstructured":"World Federation of Hemophilia.Alnylam Suspends Fitusiran Dosing Due to Thrombotic Event in Phase 2 Open\u2010Label Extension Study [Internet].2017. [cited 2018 March 6] Available from:https:\/\/news.wfh.org\/alnylam\u2010suspends\u2010fitusiran\u2010dosing\u2010due\u2010thromboticevent\u2010phase\u20102\u2010open\u2010label\u2010extension\u2010study\/"},{"key":"e_1_2_8_88_1","unstructured":"World Federation of Hemophilia.Update: FDA Lifts Suspension of Fitusiran Trial.2017. [cited 2018 March 6] Available from:https:\/\/news.wfh.org\/update\u2010fda\u2010lifts\u2010suspension\u2010fitusiran\u2010trial\/"},{"key":"e_1_2_8_89_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-150273"},{"key":"e_1_2_8_90_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-155018"},{"key":"e_1_2_8_91_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12864"},{"key":"e_1_2_8_92_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001542"},{"key":"e_1_2_8_93_1","unstructured":"National Hemophilia Foundation.Three Concizumab Trials Halted by Novo Nordisk.2020. [cited 2020 March 17]. Available from:https:\/\/www.hemophilia.org\/news\/three\u2010concizumab\u2010trials\u2010halted\u2010by\u2010novo\u2010nordisk\/"},{"issue":"1","key":"e_1_2_8_94_1","first-page":"85","article-title":"A phase 1b\/2 study of the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of PF\u201006741086, an anti\u2010TFPI monoclonal antibody, in patients with severe hemophilia A or B","volume":"3","author":"Mahlangu J","year":"2019","journal-title":"Res Pract Haemost Thromb"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.18379","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.18379","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.18379","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T18:19:24Z","timestamp":1692641964000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.18379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,23]]},"references-count":93,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1111\/bjh.18379"],"URL":"https:\/\/doi.org\/10.1111\/bjh.18379","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,23]]},"assertion":[{"value":"2022-04-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}